San Diego, CA
September 10, 2015
Metabiomics is pleased to be attending the 3rd annual Global Engage Microbiome R&D and Business Collaboraton Forum. Greg Kuehn, President and COO will be giving a talk on Day 2 (sept 11) covering the company’s platform, vision and mission, clinical research program, pipeline, and opportunities for collaboration, licensing and investment.
To view a pdf of the company’s poster Click Here
For more information on the conference Click Here
Metabiomics is a Colorado and Virginia based company that is translating advances in microbiome science and technology into the creation of new diagnostics, therapeutics and personalized medicine products and services. Metabiomics is continuously advancing and applying patented MultiTag™ DNA sequencing technology and a metagenomics discovery platform to pursue innovative molecular systems biology, biomarker discovery and clinical research aimed at the detection and prevention of colon cancer and other gastrointestinal cancerous, autoimmune and infectious diseases.